Compare AIOT & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIOT | BNTC |
|---|---|---|
| Founded | 1993 | 1995 |
| Country | United States | United States |
| Employees | 1954 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 434.6M | 360.7M |
| IPO Year | N/A | 2020 |
| Metric | AIOT | BNTC |
|---|---|---|
| Price | $3.74 | $12.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $10.33 | ★ $27.67 |
| AVG Volume (30 Days) | ★ 1.9M | 92.6K |
| Earning Date | 06-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 80.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $24.46 | N/A |
| Revenue Next Year | $9.01 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.78 | $9.85 |
| 52 Week High | $5.88 | $16.76 |
| Indicator | AIOT | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 46.05 | 58.84 |
| Support Level | $3.66 | $11.40 |
| Resistance Level | $5.69 | $13.80 |
| Average True Range (ATR) | 0.26 | 0.85 |
| MACD | -0.06 | 0.25 |
| Stochastic Oscillator | 6.94 | 61.55 |
PowerFleet Inc is engaged in Internet-of-Things (IoT) solutions providing valuable business intelligence for managing high-value enterprise assets that improve operational efficiencies. It provide critical information that powers unified operations throughout organizations. It is solving the challenge of inefficient data collection, real-time visibility, and analysis that leads to transformative business operations. Its SaaS cloud-based applications take data from IoT devices and ecosystem of third-party and partner applications to present actionable information for customer.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.